Armata Pharmaceuticals Q3 2026 swings to net profit of $54.86 million
ARMP•Armata Pharmaceuticals reported third-quarter 2026 net income of $54.86 million, driven primarily by a $69.6 million convertible loan fair-value gain. Grant and award revenue more than doubled to $3.17 million, and cash and cash equivalents were $18.32 million at September 30.
1. Quarterly results
Armata Pharmaceuticals swung to third-quarter 2026 net income of $54.86 million, primarily driven by a $69.6 million fair-value gain on a convertible loan. Grant and award revenue more than doubled year over year to $3.17 million. Cash and cash equivalents were $18.32 million at September 30, compared with December 31, 2025.
2. AP-SA02 update
AP-SA02 received FDA Breakthrough Therapy designation for adjunct treatment of complicated bacteremia caused by MSSA or MRSA. A planned Phase 3 superiority study is expected to begin in the second half of 2026, pending FDA protocol concurrence.
